… Although the small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) erlotinib and gefitinib have modest clinical benefits after platinum-based …

… clinical efficacy. These are most often substitution mutations or in-frame deletions arising in
exons 19 or 21 (City of Hope Molecular Diagnostic Laboratory, 2010). In NSCLC, mutations …

… Two clinical reports contain data of the efficacy of erlotinib for advanced or recurrent non-adenocarcinoma
NSCLC patients harboring EGFR mutations. These two reports were …

… We reviewed the available results of clinical trials interested … A randomized placebo-controlled
trial of erlotinib in patients … The results clearly favour erlotinib with a better progression-…

… -EGFR agents such as gefitinib and erlotinib. Early results on the relationship between EGFR
… However, these results are confounded by the prognostic value of the mutations, since it …

… In preclinical testing, oral gefitinib inhibited the growth of NSCLC tumors that express the …
symptoms and radiographic tumor shrinkages with gefitinib.ObjectiveTo assess differences in …

… gefitinib in patients who received a 3rd-G EGFR-TKI following discontinuation of study …
showed similar results to the analyses we conducted in this study. Our results showed that …

… in EGFR-mutant tumors, and clinical studies have shown a positive … to progression after
treatment with gefitinib or erlotinib.3, 4 … about the clinical efficacy of pembrolizumab plus erlotinib. …

… We further explored the efficacy of gefitinib administration as a first-line treatment for EGFR
… the type of EGFR tyrosine kinase inhibitor (gefitinib or erlotinib) studied, given that all patients …

… clinical data suggest that these tumors still depend on signaling through the EGFR pathway.
This article reports the results of a trial combining erlotinib … with gefitinib or erlotinib within …